Standout Papers

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough ... 2022 2026 2023 2024161
  1. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials (2022)
    Lorcan McGarvey, Surinder S. Birring et al. The Lancet

Immediate Impact

3 standout

Citing Papers

Interstitial Lung Disease
2024 Standout
TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases
2023 Standout
3 intermediate papers

Works of Jonathan Schelfhout being referenced

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
2022 Standout
Prevalence and Burden of Chronic Cough in the United States
2021
and 2 more

Author Peers

Author Last Decade Papers Cites
Jonathan Schelfhout 582 504 119 204 52 711
Xianghuai Xu 519 314 293 84 73 645
Ha‐Kyeong Won 410 455 48 133 40 706
Sung‐Yoon Kang 377 386 41 126 63 645
Jason Powell 373 172 81 32 48 837
Rosana Câmara Agondi 402 455 15 34 36 693
Matthew G. Marin 409 229 6 76 36 779
Kang‐Cheng Su 465 354 42 22 43 710
Alessandro Bodini 450 480 15 51 33 770
Julian McGlashan 278 250 144 37 51 619
Brett Haumann 680 630 9 19 29 777

All Works

Loading papers...

Rankless by CCL
2026